دورية أكاديمية
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy lenvatinib alone for advanced hepatocellular carcinoma
| العنوان: | Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy lenvatinib alone for advanced hepatocellular carcinoma |
|---|---|
| المؤلفون: | Min-Ke He, Run-Bin Liang, Yang Zhao, Yu-Jie Xu, Huan-Wei Chen, Yuan-Min Zhou, Zhi-Cheng Lai, Li Xu, Wei Wei, Yao-Jun Zhang, Min-Shan Chen, Rong-Ping Guo, Qi-Jiong Li, Ming Shi |
| المصدر: | Therapeutic Advances in Medical Oncology, Vol 13 (2021) |
| بيانات النشر: | SAGE Publishing, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for advanced hepatocellular carcinoma. Considering different anti-malignancy mechanisms, combining these three treatments may improve outcomes. This study aimed to compare the efficacy and safety of lenvatinib, toripalimab, plus HAIC versus lenvatinib for advanced hepatocellular carcinoma. Methods: This was a retrospective study including patients treated with lenvatinib [8 mg (⩽60 kg) or 12 mg (>60 kg) once daily] or lenvatinib, toripalimab plus HAIC [LeToHAIC group, lenvatinib 0–1 week prior to initial HAIC, 240 mg toripalimab 0–1 day prior to every HAIC cycle, and HAIC with FOLFOX regimen (oxaliplatin 85 mg/m 2 , leucovorin 400 mg/m 2 , 5-fluorouracil bolus 400 mg/m 2 on day 1, and 5-fluorouracil infusion 2400 mg/m 2 for 46 h, every 3 weeks)]. Progression-free survival, overall survival, objective response rate, and treatment-related adverse events were compared. Results: From February 2019 to August 2019, 157 patients were included in this study: 71 in the LeToHAIC group and 86 in the lenvatinib group. The LeToHAIC group showed longer progression-free survival (11.1 versus 5.1 months, p |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1758-8359 17588359 |
| Relation: | https://doaj.org/toc/1758-8359 |
| DOI: | 10.1177/17588359211002720 |
| URL الوصول: | https://doaj.org/article/4d8d01bd04af49ef8dd01017c4f1c005 |
| رقم الأكسشن: | edsdoj.4d8d01bd04af49ef8dd01017c4f1c005 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 17588359 |
|---|---|
| DOI: | 10.1177/17588359211002720 |